Boston Therapeutics Awarded Key European Patent

Boston Therapeutics Awarded Key European Patent

Download PDF

Protecting BTI-320 Composition of Matter

LAWRENCE, Mass., April 06, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics (the “Company” or “BTI”) (OTCQB:BTHE) is pleased to announce that it has won a patent position argued with the European Patent and Trademark Office this week.  The patent has claims for the composition of matter in the use of specific low and high molecular weight mannan polysaccharides to inhibit the enzymes that break down starches into simple sugars, allowing for absorption in the gut.  This is a core technology of BTI-320 and SUGARDOWN® products that have been shown to effectively block absorption of sugar to minimize post meal spikes in glucose levels in patients with glucose intolerance or Type 2 diabetes.

Boston Therapeutics CEO Carl W. Rausch successfully defended the case personally at an oral proceeding in Rijswijk, Holland.  He noted, “This was an important case to win for the Company and we were confident that we had the data that would convince the Examiners of our inventiveness.”  The company intends to pursue global commercialization of these products as an FDA regulated material and as a prescription formulation.  This key composition allows for “combination” with many other generic compounds and will breathe new exclusivity and new efficacy opportunities for precision medicine.  The growing acceptance of the one to two hour post prandial sugar elevation is a new key technology driver for precise, and easily observed self-blood-glucose management.

About Boston Therapeutics, Inc. 
Boston Therapeutics, headquartered in Lawrence, MA (OTCQB:BTHE) and with an office in Albuquerque, NM is an innovator in design, development and commercialization of compounds to treat diabetes and diabetes related complications.

Forward Looking Statement
This press release includes forward-looking statements. These statements may be identified by words such as "feel," "believes," expects," "estimates," "projects," "intends," "should," "is to be," or the negative of such terms, or other comparable terminology. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein. Factors that could cause actual results to differ materially include, but are not limited to: our limited operations and need to expand in the near future; risks associated with obtaining regulatory approval of our products; the ability to protect our intellectual property; the potential lack of market acceptance of our products; potential competition; our inability to retain key members of our management team; our inability to raise additional capital to fund our operations and business plan; our ability to continue as a going concern; our liquidity and other risks and uncertainties and other factors discussed from time to time in our filings with the Securities and Exchange Commission ("SEC"), including our annual report on Form 10-K filed with the SEC. Boston Therapeutics expressly disclaims any obligation to publicly update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.

Contact: Boston Therapeutics, Inc.
Loraine Upham, COO 
Phone: 603-935-9799

Primary Logo

Source: Boston Therapeutics, Inc.